Publications by authors named "Gladys Telliam"
Methods: We used a patient-specific induced pluripotent stem cell (iPSC) line treated with the mutagenic agent N-ethyl-N-nitrosourea (ENU). Genomic instability was validated using γ-H2AX and micronuclei assays and CGH array for genomic events.
Results: An increased number of progenitors (x5-Fold), which proliferated in liquid cultures with a blast cell morphology, was observed in the mutagenized condition as compared to the unmutagenized one.
Article Synopsis
- The study aimed to create an in vitro model of chronic myeloid leukemia (CML) progression, focusing specifically on the blast crisis stage, to discover new treatment targets.
- Researchers mutagenized different CML-derived induced pluripotent stem cell (iPSC) lines using the alkylating agent ENU, examining their properties after 12 days of hematopoietic differentiation, including their gene expression.
- Results showed that one mutated iPSC line produced myeloid blasts with specific markers and displayed a delayed differentiation compared to controls, highlighting CD25 as a potential marker for CML progression in patients.
Article Synopsis
- Aryl Hydrocarbon Receptor (AHR) is a transcription factor that plays key roles in biological processes such as cell division and inflammation, and is crucial for the maintenance of hematopoietic stem cells (HSC).
- Research found that AHR expression is significantly reduced in CML (Chronic Myeloid Leukemia) cells compared to healthy counterparts, suggesting its involvement in leukemia progression.
- Treatment with AHR antagonist StemRegenin (SR1) increased leukemic cell proliferation, while the natural AHR agonist FICZ reduced the number of CD34+ CML cells and their clonogenic ability, indicating AHR's potential as a therapeutic target in CML.
To model the developmental pattern of human prothymocytes and thymopoiesis, we used NOD-scid/γc(-/-) mice grafted with human umbilical cord blood CD34(+) hematopoietic progenitor cells (HPCs). Human prothymocytes developed in the murine bone marrow (BM) from multipotent CD34(++)CD38(lo)lineage(-) HPCs to CD34(++)CD7(+)CD2(-) pro-T1 cells that progressed in a Notch-dependent manner to CD34(+)CD7(++)CD2(+) pro-T2 cells, which migrated to the thymus. BM prothymocyte numbers peaked 1 mo after graft, dropped at mo 2, and persisted at low levels thereafter, with only a few CD34(+)CD7(lo) prothymocytes with limited T potential being detected by mo 5.
View Article and Find Full Text PDF